These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 9413091)
41. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282 [TBL] [Abstract][Full Text] [Related]
42. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. Voss G; Dittmer U; Coulibaly C; Makoschey B; Petry H; Lüke W; Hunsmann G J Gen Virol; 1993 Sep; 74 ( Pt 9)():1757-63. PubMed ID: 8376957 [TBL] [Abstract][Full Text] [Related]
43. Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy. Mills KH; Page M; Kitchin P; Chan L; Jones W; Silvera P; Corcoran T; Flanagan B; Ling C; Thiriart C J Med Primatol; 1993; 22(2-3):104-9. PubMed ID: 8411102 [TBL] [Abstract][Full Text] [Related]
44. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316 [TBL] [Abstract][Full Text] [Related]
45. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. Arthur LO; Bess JW; Chertova EN; Rossio JL; Esser MT; Benveniste RE; Henderson LE; Lifson JD AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S311-9. PubMed ID: 9814959 [TBL] [Abstract][Full Text] [Related]
46. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331 [TBL] [Abstract][Full Text] [Related]
47. Vaccine-induced CD4+ T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity. Mills KH; Barnard AL; Williams M; Page M; Ling C; Stott EJ; Silvera P; Taffs F; Kingsman AS; Adams SE J Immunol; 1991 Nov; 147(10):3560-7. PubMed ID: 1719081 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. Lifson JD; Rossio JL; Piatak M; Bess J; Chertova E; Schneider DK; Coalter VJ; Poore B; Kiser RF; Imming RJ; Scarzello AJ; Henderson LE; Alvord WG; Hirsch VM; Benveniste RE; Arthur LO AIDS Res Hum Retroviruses; 2004 Jul; 20(7):772-87. PubMed ID: 15307924 [TBL] [Abstract][Full Text] [Related]
49. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. Amara RR; Smith JM; Staprans SI; Montefiori DC; Villinger F; Altman JD; O'Neil SP; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McNicholl JM; McClure HM; Moss B; Robinson HL J Virol; 2002 Jun; 76(12):6138-46. PubMed ID: 12021347 [TBL] [Abstract][Full Text] [Related]
50. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout. Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006 [TBL] [Abstract][Full Text] [Related]
51. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693 [TBL] [Abstract][Full Text] [Related]
52. Construction of recombinant vaccinia virus expressing Rinderpest Virus nucleocapsid protein and its immunogenicity in mice. Ohishi K; Kamata H; Ohkubo S; Yamanouchi K; Kai C J Vet Med Sci; 1998 May; 60(5):655-6. PubMed ID: 9637306 [TBL] [Abstract][Full Text] [Related]